{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:37:15Z","timestamp":1767829035058,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients with metastatic castration\u2010resistant prostate cancer (mCRPC), bone is a dominant site of metastasis. Bone metastases often lead to skeletal\u2010related events (SREs), which include pain, spinal cord compression and fractures. The treatment of bone metastases in men with mCRPC aims to improve SRE\u2010free survival, quality of life and clinical outcomes. Effective treatment options include antiresorptive bone\u2010targeted agents such as zoledronic acid and denosumab, and radium\u2010223, a bone\u2010targeting radiopharmaceutical. Although overseas and local guidelines have widely recommended using either zoledronic acid or denosumab for the prevention of SREs in men with mCRPC and associated bone metastases, current evidence suggests that denosumab is superior to zoledronic acid in terms of longer SRE\u2010free time and fewer total SREs observed in patients.<\/jats:p>","DOI":"10.1111\/ajco.13315","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T16:56:48Z","timestamp":1598547408000},"page":"4-6","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing skeletal\u2010related events prevention in patients with advanced prostate cancer"],"prefix":"10.1111","volume":"16","author":[{"given":"Angus Kwong\u2010Chuen","family":"Leung","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong  Shatin Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu103"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2017.321"},{"key":"e_1_2_5_4_1","volume-title":"Zoledronic Acid Prescribing Information","year":"2018"},{"key":"e_1_2_5_5_1","volume-title":"Denosumab Prescribing Information","year":"2018"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70473-4"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70303-1"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0269"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.4.490"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01658"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.002"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1932-2"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1039\/b704726f"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70474-7"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0251-x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0036"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.2526"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.10.104"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.06.002"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14489"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14091"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13315","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:49:10Z","timestamp":1693907350000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":25,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/ajco.13315"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13315","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"2020-08-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}